Clinical Trial Categories
Breast Trials
Trial ID ESR 22-21698 (EIMPRIS)
NCT05438498clinicaltrials.gov ID
Phase II/III
Trial ID 21455
NCT05296798clinicaltrials.gov ID
USOR ID: 21455
Phase III
Phase III, 2 Arm, Randomized, Open Label, Multicenter, Registrational Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo (+/- Endocrine Therapy) After Induction Chemotherapy (Phesgo+Taxane) In Patients With Previously Untreated Her2-Positive, Estrogen Receptor Positive Locally Advanced Or Metastatic Breast Cancer
Trial ID 17079
NCT03053193clinicaltrials.gov ID
USOR ID: 17079
FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry
Trial ID
NCT04916808clinicaltrials.gov ID
Trial ID 21448
NCT05113966clinicaltrials.gov ID
USOR ID: 21448
Phase II
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting (G1T28-213)
Trial ID 19226
NCT04546009clinicaltrials.gov ID
USOR ID: 19226
Phase III
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Trial ID 20363
NCT04711252clinicaltrials.gov ID
USOR ID: 20363
Phase III
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Trial ID 20396
NCT04784715clinicaltrials.gov ID
USOR ID: 20396
Phase III
DESTINY09: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer
Trial ID 20326
NCT04906395clinicaltrials.gov ID
USOR ID: 20326
Phase III
OVELIA: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Trial ID 21462
NCT05232916clinicaltrials.gov ID
USOR ID: 21462
Phase III
FLAMINGO-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy
Trial ID 22080
USOR ID: 22080
Phase III
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant(AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with HR+/HER2- early breast cancer and a intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence
Trial ID 22101
NCT05514054clinicaltrials.gov ID
USOR ID: 22101
Phase III
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Trial ID 21380
NCT05169567clinicaltrials.gov ID
USOR ID: 21380
Phase III
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Trial ID 20289
NCT04254107clinicaltrials.gov ID
USOR ID: 20289
Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Trial ID 21494
NCT05304962clinicaltrials.gov ID
USOR ID: 21494
Phase I
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Trial ID 14059
NCT03379428clinicaltrials.gov ID
USOR ID: 14059
Phase I/II
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Trial ID 20266
NCT04485013clinicaltrials.gov ID
USOR ID: 20266
Phase Ib
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies
Trial ID
NCT04589845clinicaltrials.gov ID
Phase II
Trial ID 21501
NCT05065411clinicaltrials.gov ID
USOR ID: 21501
Phase II
ARTEST: A Phase 2 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treated Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib